IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares

Stock News

2025/11/07

IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1174217431"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174217431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174217431?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174217431","market":"us","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-07 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1174217431","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174217431","pubTimestamp":1762512132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B(01541)执行董事田文智增持5万股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}